Tianwen Yin

发表

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study

Jinming Yu, Xia Fang, F. Teng, 2021, Frontiers in Oncology.

Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer

Jinming Yu, F. Teng, Peiliang Wang, 2021, Journal of Cancer Research and Clinical Oncology.

E cacy of Single-site Radiotherapy Plus PD-1 Inhibitors vs PD-1 Inhibitors for Oligometastatic Non-Small Cell Lung Cancer

Peiliang Wang, Tianwen Yin, Kaikai Zhao, 2021 .

CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway

Zhihua Wen, Yufeng Cheng, Tianyu Liu, 2022, Discover Oncology.

Treatment-related lymphopenia impairs the treatment response of anti-PD-1 therapy in esophageal squamous cell carcinoma.

F. Teng, Jinming Yu, Peiliang Wang, 2022, International immunopharmacology.

The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?

Jinming Yu, H. Xin, F. Teng, 2021, Biomarker research.

Optimum fractionation of radiation to combine PD‐1 blockade

F. Teng, Peiliang Wang, Tianwen Yin, 2023, MedComm.

Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer

Peiliang Wang, Tianwen Yin, Xiaonan Shi, 2024, Thoracic Cancer.

Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition

Peiliang Wang, Tianwen Yin, Xiaonan Shi, 2024, Oncoimmunology.